LISATA THERAPEUTICS, INC. — Director's Dealing 2011

Aug 19, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2011-08-17

Reporting Person: Pecora Andrew L (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-08-17	Stock Option (Right to Purchase)	$0.71	A	500000	Acquired	2021-08-16	Common Stock (500000)	Direct

Footnotes

F1: On August 17, 2011, the effective date of an amendment to the Reporting Person's employment agreement with the Issuer and Progenitor Cell Therapy, LLC, a wholly-owned subsidiary of the Issuer, pursuant to which the Reporting Person was appointed Chief Medical Officer of the Issuer, the Reporting Person was granted an option to purchase up to 500,000 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), subject to the terms and conditions of the Issuer's 2009 Equity Compensation Plan.

F2: This option vested as to 100,000 shares on August 17, 2011, and is scheduled to vest as to 100,000 shares on each of August 17, 2012, August 17, 2013, August 17, 2014 and August 17, 2015, provided that the Reporting Person remains employed by the Issuer on such dates.